Pretty much everyone has heard of sleepwalking – and some of us even do it from time to time. But sleep cooking and sleep driving? Engaging in such activities while not awake – a phenomenon known as ...

(Reuters) -Swiss drugmaker Idorsia said on Monday it has received the U.S. Food and Drug Administration's approval for its treatment for insomnia in adult patients. The drug, to be available under the ...

The U.S. Food and Drug Administration is asking several drug manufacturers to strengthen product warning labels for many sleep medications because of risks that people will do things they don’t ...

This Nature Outlook is editorially independent, produced with financial support from Avadel. Miranda cannot remember a time in her life when she did not have insomnia. The 23 year old, who asked for ...

ATS 2023, Washington, DC – Chronic obstructive pulmonary disease patients newly prescribed non-benzodiazepine benzodiazepine receptor agonists (NBZRAs) such as zolpidem (Ambien, Intermezzo and other ...

(Reuters) - The U.S. health regulator warned that taking a widely prescribed insomnia drug at night may impair driving and alertness the next morning, and recommended the bedtime dose be lowered. New ...

To better understand why some people develop the condition while others do not, researchers have worked together to identify ...

A few years ago, drug giant Bristol-Myers Squibb Co. announced it was retooling its strategy, meaning a drug it was developing for insomnia was probably headed for the sidelines. Vanda Pharmaceuticals ...

The U.S. Food and Drug Administration approved Belsomra (suvorexant) tablets for use as needed to treat insomnia. Belsomra is an orexin receptor antagonist and is the first approved drug of this type.

Two drugs have emerged as the optimal medications for treating insomnia based on the "best-available evidence," but there are caveats. In a comprehensive comparative-effectiveness analysis, ...

Persistent sleeplessness stems from a variety of factors, all of which should be addressed if a treatment plan is to succeed long-term. While many patients (10%-40% of the population) complain about ...